Third Rock Ventures II, L.P.

Third Rock Ventures II, L.P. is a declared insider at 7 companies; the most frequent names are Sage Therapeutics, Inc., Global Blood Therapeutics, Inc. and MyoKardia, Inc. The record holds 82 filings, for trades running from 23 July 2014 to 15 September 2021.

Market trades split into 1 purchase (€2.6M) and 22 sales (€236.8M). Sales outweigh purchases by €234.2M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2021: no purchases and 6 sales on the market.

The latest filing, published on 17 September 2021, reports a transaction in Jounce Therapeutics, Inc. The last insider purchase was made public on 6 November 2017, 3,273 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.